Haemonetics (HAE) vs Stevanato Group S.p.A. (STVN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Haemonetics (HAE) has outperformed Stevanato Group S.p.A. (STVN) over the past year, gaining 106.5% versus a loss of 19.2%. Over five years, HAE leads with a +45.5% price change compared with -20.1% for STVN. Haemonetics is the larger company by market cap ($5.44 billion vs $5.25 billion), about 1.0 times the size.
On valuation, Haemonetics trades at a lower forward P/E (20.7x vs 23.0x for Stevanato Group S.p.A.).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HAE | STVN |
|---|---|---|
| Share price | $119.59 | $19.21 |
| Market cap | $5.44B | $5.25B |
| 1-day change | +17.58% | -1.18% |
| YTD return | +26.90% | -3.38% |
| 1-year return | +106.48% | -19.20% |
| 5-year return | +45.49% | -20.07% |
| P/E ratio (TTM) | 57.77 | 33.70 |
| Forward P/E | 20.70 | 23.02 |
| EPS (TTM) | $2.07 | $0.57 |
| Dividend yield | 0.00% | 0.32% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.33B | — |
| Revenue growth (YoY) | -1.97% | — |
| Net income (latest FY) | $97.31M | — |
| Gross margin | 59.04% | — |
| Operating margin | 11.75% | — |
| Net margin | 7.29% | — |
| 52-week high | $120.72 | $27.99 |
| 52-week low | $48.17 | $12.89 |
| Distance from 52-week high | -0.94% | -31.37% |
| Analyst consensus | buy | buy |
| Avg. price target upside | -6.76% | +28.47% |
| Average volume | 678.94K | 370.27K |
| Shares outstanding | 45.50M | 49.83M |
| Employees | 3,009 | 6,010 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HAE has outperformed STVN by 125.7 percentage points over the past year.
- Haemonetics trades at a higher earnings multiple (57.8x vs 33.7x trailing P/E).
About Haemonetics
HAE stock →Haemonetics Corporation, a medical technology company, provides a suite of hospital technologies solutions. The company operates through Plasma, Blood Center, and Hospital segments.
Health Care · Medical/Dental Instruments · 3,009 employees
About Stevanato Group S.p.A.
STVN stock →Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific.
Health Care · Medical/Dental Instruments · 6,010 employees
HAE vs STVN FAQ
Which is bigger, Haemonetics or Stevanato Group S.p.A.?
Haemonetics (HAE) is larger, with a market capitalization of $5.44B compared with $5.25B for Stevanato Group S.p.A. (STVN).
Which stock has performed better over the past year, HAE or STVN?
HAE returned +106.48% over the past 12 months, compared with -19.20% for STVN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, HAE or STVN?
STVN has the lower trailing P/E at 33.7, versus 57.8 for HAE. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Haemonetics or Stevanato Group S.p.A.?
Stevanato Group S.p.A. pays a dividend yielding 0.32%, while Haemonetics does not currently pay a regular dividend.
Are Haemonetics and Stevanato Group S.p.A. in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.